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Summary
Background and purpose: Metabolic syndrome and chronic kidney disease (CKD) have received
attention as new risk factors for cardiovascular disease. This study evaluated differences in key
risk factors between acute coronary syndrome (ACS) and stable angina pectoris (SAP) by using
traditional coronary risk factors, metabolic syndrome, and CKD.
Methods: Among 1890 consecutive patients admitted to our institution, we studied 140 patients
with initially diagnosed ACS and 163 patients with initially diagnosed SAP and compared risk
factors between the two groups. Next, the relationship between smoking status after the initial
diagnosis of coronary artery disease (CAD) and the incidence of subsequent cardiac event was
examined after discharge in 284 patients.
Results: Adjusted multivariate analysis showed that only current smoking was an independent
predictor of ACS (odds ratio, 2.20; 95% CI, 1.28—3.78; p = 0.004) among all risk factors we
examined. Treatment with a calcium-channel blocker had a preventive effect on ACS (odds
ratio, 0.44; 95% CI, 0.26—0.75; p = 0.003), but treatment with a beta-blocker did not. Patients
who continued to smoke after CAD was diagnosed had a risk of cardiac events about 5 times
that of smokers who quit (adjusted hazard ratio, 5.05; 95% CI, 1.33—19.20; p = 0.02).
∗ Corresponding author. Tel.: +81 3 3433 1111; fax: +81 3 3459 6043.
E-mail address: yagi@jikei.ac.jp (H. Yagi).
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Conclusions: The risk factors were signiﬁcantly different between initially diagnosed ACS and
SAP. Smoking was a more important risk factor of initially diagnosed ACS. Smoking cessation might
have a preventive effect on subsequent cardiac events. Also, we found that treatment with a
calcium-channel blocker would help prevent ACS in Japanese patients.
© 2010 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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of 1 or more of the following 3 lipid disorders at ﬁrst
fasting blood sampling or both: a low-density lipoprotein
(LDL) cholesterol level ≥140mg/dL, a triglyceride levelntroduction
moking is a risk factor for coronary artery disease (CAD).
he risk of acute myocardial infarction increases with the
umber of cigarettes smoked per day [1—3]. In addition, the
isk of CAD decreases with smoking cessation. The risk for
second coronary event after acute myocardial infarction
lso decreases with smoking cessation [3—7].
The main cause of CAD is atherosclerosis [8—10]. Multiple
rocesses in addition to smoking are involved in the devel-
pment of atherosclerosis [11,12]. Many studies examining
he prevention of CAD have focused on how the progression
f atherosclerosis can be slowed. In recent years, metabolic
yndrome and chronic kidney disease (CKD) have received
ttention as new risk factors for cardiovascular disease.
tudies have shown that metabolic syndrome and CKD indi-
idually increase the risk of CAD and the cardiovascular
ortality rate [13—16].
However, the risk factors for acute coronary syndrome
ACS) have not been deﬁnitively analyzed. Given tradi-
ional risk factors and newly identiﬁed risk factors, such as
etabolic syndrome and CKD, whether smoking remains a
owerful risk factor for ACS is unclear. What is the most
mportant risk factor for the shift of the initial manifesta-
ion of CAD to ACS? ACS is a life-threatening condition, which
ften leads to sudden death. Therefore, preventing ACS is
xtremely important. In the present study, we attempted
o determine the key risk factors associated with ACS, from
mong traditional risk factors and newly identiﬁed risk fac-
ors, by comparing the risk factors for ACS with those for
table angina pectoris (SAP). We then performed a follow-up
tudy to examine the relationship between the key risk fac-
ors and subsequent cardiac events after the initial diagnosis
f CAD.
aterials and methods
ubjects and design
rom November 2004 through March 2007, coronary angiog-
aphy was performed for 1890 consecutive patients at The
ikei University School of Medicine in Tokyo, Japan. From
mong them, the following patients were enrolled in the
resent study: those in whom stenosis of 75% or more,
ased on the American Heart Association classiﬁcation, was
etected in at least 1 epicardial coronary artery and those in
hom CAD was diagnosed for the ﬁrst time. Among patients
ith stable CAD in whom coronary artery stenosis of 75% or
ore was detected, those who had had a prior myocardial
nfarction were excluded. In addition, patients with coro-
ary artery spasm in whom coronary artery stenosis of 75% or
ore was not detected were also excluded from this study.
≥
t
w
w
wFirst, patients were divided into 2 groups: those with
CS (ACS group) and those with SAP (SAP group). We exam-
ned the presence in each group of risk factors, including
etabolic syndrome, CKD, and traditional coronary risk fac-
ors.
Next, patients who had undergone initial treatment and
emained alive 3 months after discharge were re-divided
ccording to the risk factor most strongly associated with
CS. The incidence of subsequent cardiac events was then
xamined.
The study protocol (20-251[5541]) was approved by the
thics committee of The Jikei University School of Medicine.
eﬁnition of acute coronary syndrome
CS was deﬁned as the presence of acute myocardial infarc-
ion or unstable angina pectoris [17]. The diagnosis of acute
yocardial infarction referred to the ‘‘Universal deﬁnition
f myocardial infarction’’ [18] and required the presence of
ny 2 of the following 3 criteria: (1) history of chest pain,
ppression or discomfort lasting 20min or longer; (2) typi-
al electrocardiographic change (i.e. ST segment elevation
reater than 0.1mV in at least 1 standard lead or 2 pre-
ordial leads, ST segment depression greater than 0.1mV
n at least 2 leads, abnormal Q waves or T wave inversions
n at least 2 leads); (3) an increased serum level of the MB
raction of creatine kinase equivalent to more than twice
he upper limit of the normal range. All patients were hos-
italized within 1 week of the onset of acute myocardial
nfarction. Unstable angina pectoris was diagnosed when
atients had chest pain, oppression, or discomfort at rest
ithin 72 h before hospitalization without an increase in the
erum level of the MB fraction of creatine kinase to more
han twice the upper limit of the normal range. SAP was
iagnosed when patients did not have angina at rest.
eﬁnitions of traditional risk factors
hen patients were found to have CAD, each risk factor
as examined. Hypertension was deﬁned as the pres-
nce of any of the following: systolic blood pressure
140mmHg, diastolic blood pressure ≥90mmHg, or the
se of antihypertensive agents. Dyslipidemia was diag-
osed with the use of lipid-lowering agents, the presence150mg/dL, and a high-density lipoprotein (HDL) choles-
erol level <40mg/dL [19]. The level of LDL cholesterol
as calculated with the Friedewald equation for patients
ith a serum triglyceride level <400mg/dL [20]. Diabetes
as diagnosed with the presence of any of the following:
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fasting plasma glucose level ≥126mg/dL, casual plasma glu-
cose level ≥200mg/dL, or a history of diabetes. However,
the fasting plasma glucose level in patients with ACS was
determined after an inﬂammatory reaction had resolved.
Obesity was deﬁned as a body mass index ≥25 kg/m2
[21].
Information about the treatment of risk factors at the
time of the ﬁrst examination at our hospital was obtained
from hospital medical records, questionnaires, and direct
interview of patients. Medications started just after the
onset of CAD symptoms were excluded.
Smoking status was assessed at the time of the ﬁrst
medical examination at our hospital on the basis of the
information obtained from hospital medical records, a ques-
tionnaire, and direct interview of patients. Smokers were
deﬁned as patients who had smoked cigarettes for at least 1
year. From 3 months to 1 year after patients ﬁrst underwent
treatment and were discharged, we reassessed smoking sta-
tus with the same methods 1 or more times. Patients were
re-divided into 4 groups: persistent smokers, deﬁned as
those who continued smoking after discharge; quitting smok-
ers, those who stopped smoking after discharge; former
smokers, those who had stopped smoking before the ﬁrst
examination at our hospital; never smokers, those who had
never smoked cigarettes. However, smoking cessation just
after the onset of CAD symptoms was not taken into consid-
eration.
Also, information about the history of stroke, peripheral
arterial disease, malignancy, chronic obstructive pulmonary
disease, and dialysis were obtained from hospital medical
records, questionnaires, and direct interview of patients.
Peripheral arterial disease was deﬁned as the stenotic,
occlusive, and aneurysmal diseases of the aorta and its
branch arteries that supply the brain, visceral organs, and
the limbs, exclusive of the coronary arteries [22].
Deﬁnitions of metabolic syndrome and chronic
kidney disease
Metabolic syndrome was diagnosed with the deﬁnition of the
International Diabetes Federation [23].
We estimated the glomerular ﬁltration rate (GFR)
from serum creatinine values using an abbreviated equa-
tion developed by the Japanese Society of Nephrology:
estimated GFR (mL/min/1.73m2) = 194× [serum creatinine
(mg/dL)]−1.094 × [age in years]−0.287 × [0.739 if the patient
was female] [24]. We deﬁned proteinuria as a urine pro-
tein level of 1+ or greater by dipstick analysis and deﬁned
microalbuminuria as a spot urine albumin-to-creatinine ratio
of 30—300mg albumin/g creatinine. CKD was diagnosed with
the presence of proteinuria or microalbuminuria, an esti-
mated GFR <60mL/min/1.73m2, or both.
Deﬁnition of cardiac events
The treatment that was ﬁnally performed to de novo
lesions in all patients was considered as the initial treat-
ment. The initial treatment was deﬁned as medical therapy
only, successful percutanous coronary intervention, or ini-
tial coronary artery bypass grafting surgery. A subsequent
cardiac event was deﬁned as any of the following: new or
t
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ecurrent fatal and nonfatal acute myocardial infarction,
ew or recurrent unstable angina pectoris, percutanous
oronary intervention of a new lesion, unscheduled coronary
rtery bypass grafting surgery, new occurrence or exacerba-
ion of heart failure requiring hospitalization, and cardiac
eath. Heart failure was diagnosed according to the Fram-
ngham criteria by 2 or more cardiologists [25]. Excluded
s events were target lesion revascularization, percuta-
eous coronary intervention performed for graft stenosis
r occlusion, and scheduled coronary artery bypass grafting
urgery.
tatistical analysis
ontinuous variables were compared by means of unpaired
-tests or one-way analysis of variance and are expressed
s means± SD. Categorical variables were compared by
eans of the chi-square test or Fisher’s exact test and are
xpressed as percentages. Multivariate analysis for predic-
ors of ACS among risk factors was performed with multiple
egression tests. We also performed multivariate analysis
ith multiple regression tests for drugs possibly preventing
CS among the medications used to treat risk factors.
Cumulative cardiac event-free survival curves for each
e-divided group were estimated with the Kaplan—Meier
ethod. Event time was the time from discharge from our
ospital after initial treatment to the occurrence of the
rst cardiac event. Survival curves were compared by means
f the log-rank test. The association of re-divided groups
ith cardiac events was assessed with the multivariate Cox
roportional hazards model. Statistical signiﬁcance was indi-
ated by a p-value less than 0.05. The SPSS, version 11.5,
oftware package (SPSS Inc., Chicago, IL, USA) was used to
erform all statistical analyses.
esults
haracteristics of the patients with acute coronary
yndrome
mong 1890 consecutive patients, we studied 303 patients
n whom CAD was diagnosed for the ﬁrst time and divided
hem into 140 patients of the ACS group and 163 patients of
he SAP group.
Compared with patients in the SAP group, patients in the
CS group were younger and had a lower body mass index,
igher systolic and diastolic blood pressures, higher esti-
ated GFR, and higher C-reactive protein levels (Table 1).
owever, the prevalence of metabolic syndrome did not dif-
er signiﬁcantly between the ACS group (36.4%) and the SAP
roup (38.7%). The percentage of patients with estimated
FR <60mL/min/1.73m2 was lower in the ACS group, but
he prevalence of CKD did not differ between the ACS group
39.3%) and the SAP group (49.1%; Table 2).
A comparison of traditional risk factors (Table 3) showed
hat the rate of hypertension was lower in the ACS group
han in the SAP group but that blood pressures were higher
n the ACS group because the rate of medical treatment
f hypertension was lower in the ACS group. In particular,
he rate of calcium-channel blocker (CCB) treatment was
ower in the ACS group (30.7%) than in the SAP group (50.9%,
348 H. Yagi et al.
Table 1 Clinical and laboratory characteristics in patients with initially diagnosed coronary artery disease.
ACS (n = 140) SAP (n = 163) p-Value
Age (years) 62.0± 12.1 65.8± 9.9 0.003
Male (%) 85.0 79.1 0.187
Multivessel disease (%) 47.9 50.9 0.595
Body mass index (kg/m2) 23.9± 3.4 24.7± 3.0 0.035
Waist circumference (cm) 87.4± 9.0 88.8± 9.3 0.194
Systolic blood pressure (mmHg) 144.0± 26.1 136.0± 16.0 0.002
Diastolic blood pressure (mmHg) 84.6± 16.0 79.3± 10.3 0.001
Total cholesterol (mg/dL) 196.7± 40.2 198.1± 50.4 0.780
Triglycerides (mg/dL) 123.7± 100.1 131.8± 70.4 0.409
HDL cholesterol (mg/dL) 44.7± 11.9 46.9± 12.8 0.135
LDL cholesterol (mg/dL) 126.6± 35.0 123.5± 35.5 0.439
Fasting plasma glucose (mg/dL) 108.1± 28.0 106.5± 27.9 0.614
Hemoglobin A1c (%) 5.6± 1.0 5.7± 1.1 0.630
Estimated GFR (mL/min/1.73m3) 71.1± 29.4 62.1± 25.3 0.004
Urine albumin-to-creatinin ratio (mg/g Cr) 20.0± 29.8 22.8± 39.6 0.541
C-reactive protein (mg/dL) 1.32± 2.75 0.20± 0.31 <0.0001
Stroke (%) 7.9 11.0 0.347
Peripheral arterial disease (%) 6.4 12.3 0.085
Malignancy (%) 11.4 16.0 0.256
COPD (%) 3.6 3.1 1.000
Dialysis (%) 7.9 9.2 0.677
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dACS, acute coronary syndrome; COPD, chronic obstructive pulmon
tein; LDL, low-density lipoprotein; SAP, stable angina pectoris.
= 0.0004; Table 4). The rate of hypertriglyceridemia was
ower in the ACS group, but the rates of dyslipidemia
nd of treatment with statins and ﬁbrates did not differ
etween the groups. The rates of diabetes and obesity did
ot differ between the groups, but the rate of insulin use
as lower in the ACS group. Among traditional risk fac-
ors, only current smoking was signiﬁcantly more frequent
n the ACS group (43.6%) than in the SAP group (22.1%,
= 0.00006).
When risk factors were adjusted for age and gender,
ultivariate analysis showed that only current smoking was
n independent predictor of ACS (odds ratio 2.20, 95% CI
F
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Table 2 Prevalence of metabolic syndrome, chronic kidney disea
A
Metabolic syndrome (%) 3
Central obesity (%) 4
Elevated triglycerides (%) 2
Reduced HDL cholesterol (%) 4
Elevated blood pressure (%) 6
Elevated fasting plasma glucose (%) 6
Central obesity + 2 factors (%) 2
Central obesity + 3 factors (%) 1
Central obesity + 4 factors (%)
Chronic kidney disease (%) 3
Estimated GFR < 60mL/min/1.73m3 (%) 2
Proteinuria (%)
Microalbuminuria (%) 1
ACS, acute coronary syndrome; GFR, glomerular ﬁltration rate; HDL, hisease; GFR, glomerular ﬁltration rate; HDL, high-density lipopro-
.28—3.78; p = 0.004; Table 5). Furthermore, among the
edications used to treat risk factors, CCBs were identiﬁed
s possibly having a preventive effect on ACS (odds ratio
.44, 95% CI 0.26—0.75; p = 0.003), whereas beta-blockers
id not (Table 6).ollow-up results
moking status could be determined after discharge for 284
atients (Table 7). The ratios of the initial treatment in each
roup were shown in Table 7. Background clinical charac-
se, and each component condition.
CS SAP p-Value
6.4 38.7 0.691
8.6 50.9 0.684
2.1 33.7 0.026
6.4 45.4 0.858
8.6 84.7 0.001
1.4 55.2 0.274
1.4 15.3 0.170
0.0 16.6 0.096
5.0 6.7 0.521
9.3 49.1 0.087
7.1 39.3 0.026
8.0 11.6 0.318
6.9 15.9 0.820
igh-density lipoprotein; SAP, stable angina pectoris.
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Table 3 Prevalence of traditional risk factors.
ACS SAP p-Value
Hypertension (%) 62.9 76.1 0.012
Dyslipidemia (%) 77.9 79.8 0.687
High LDL cholesterol (%) 49.3 57.7 0.145
High triglycerides (%) 22.1 33.7 0.026
Low HDL cholesterol (%) 42.1 33.7 0.132
Diabetes (%) 32.1 35.0 0.604
Obesity (%) 33.6 42.9 0.095
Current smoker (%) 43.6 22.1 0.00006
Cigarettes/day 25.3± 10.2 24.6± 14.1 0.764
Smoking duration (years) 34.3± 10.6 37.9± 8.8 0.089
Former smoker (%) 27.1 47.9 0.0002
Never smoker (%) 29.3 30.1 0.883
ACS, acute coronary syndrome; HDL, high-density lipoprotein; LDL, low
Table 4 Medications at the time of the ﬁrst examination.
ACS SAP p-Value
Antihypertensive agents (%) 47.1 66.3 0.001
ACE inhibitor (%) 6.4 12.3 0.085
ARB (%) 23.6 35.0 0.030
Ca-channel blocker (%) 30.7 50.9 0.0004
Beta-blocker (%) 17.1 14.1 0.467
Alpha-blocker (%) 3.6 6.2 0.427
Lipid-lowering agents (%) 25.7 34.4 0.103
Statin (%) 20.0 26.4 0.191
Fibrate (%) 3.6 4.3 0.778
Antidiabetic agents (%) 20.0 28.2 0.098
Insulin (%) 5.7 12.3 0.049
Sulfonylurea (%) 12.9 12.3 0.878
Biguanide (%) 4.3 4.9 0.797
Alpha-glucosidase inhibitor (%) 5.7 11.0 0.099
Glinide (%) 0.7 0.6 1.000
Thiazolidinedione (%) 0.7 3.1 0.222
ACE, angiotensin-converting enzyme; ACS, acute coronary syn-
drome; ARB, angiotensin receptor blocker; SAP, stable angina
pectoris.
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Table 5 Age- and gender-adjusted odds ratios of risk factors for
Beta coefﬁcient
Current smoker 0.79
Obesity −0.65
Hypertension −0.44
Older age 0.02
Metabolic syndrome 0.34
Chronic kidney disease −0.29
Male sex 0.35
Dyslipidemia −0.19
Diabetes −0.02-density lipoprotein; SAP, stable angina pectoris.
eristics that differed among the 4 smoking-status groups
ere age, gender, previous ACS, history of malignancy, and
nitial successful percutaneous coronary intervention. We
xamined the relationship between smoking status after
he initial diagnosis of CAD and the incidence of subse-
uent cardiac events. The smoking cessation rate from 3
onths to 1 year after hospital discharge was 57.7%. The
ean follow-up period was 927.2± 355.6 days (median, 973
ays).
The rate of cardiac event-free survival was signiﬁcantly
igher for quitting smokers (94.6%) than for persistent smok-
rs (74.2%, log-rank test, p = 0.004; Fig. 1). In fact, the
urvival rate of quitting smokers was similar to that of
ormer smokers (87.6%, log-rank test, p = 0.131) and never
mokers (89.3%, log-rank test, p = 0.177). After adjustment
or variables that differed among the 4 groups (age, gender,
revious ACS, history of malignancy, and initial success-
ul percutaneous coronary intervention), the risk of cardiac
vents for persistent smokers was 5 times that for quitting
mokers (adjusted hazard ratio 5.05, 95% CI 1.33—19.20;
= 0.02). In other words, smoking cessation after the initial
iagnosis of CAD was useful for reducing the risk of recurrent
ardiac events (80.2% risk reduction).
acute coronary syndrome.
Odds ratio 95% CI p-Value
2.20 1.28—3.78 0.004
0.52 0.29—0.92 0.025
0.64 0.37—1.11 0.114
1.02 0.99—1.04 0.165
1.40 0.78—2.50 0.254
0.75 0.45—1.25 0.268
1.42 0.74—2.70 0.290
0.83 0.45—1.50 0.528
0.98 0.59—1.64 0.937
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Table 6 Odds ratios of medications at the time of the ﬁrst hospital examination for acute coronary syndrome.
Beta coefﬁcient Odds ratio 95% CI p-Value
Ca-channel blocker −0.83 0.44 0.26—0.75 0.003
Beta-blocker 0.76 2.15 1.04—4.41 0.038
Insulin −0.69 0.50 0.20—1.28 0.149
Alpha-glucosidase inhibitor −0.74 0.48 0.17—1.33 0.157
ACE inhibitor −0.62 0.54 0.22—1.30 0.169
Sulfonylurea 0.56 1.76 0.73—4.21 0.205
Thiazolidinedione −1.42 0.24 0.02—2.69 0.249
ARB −0.30 0.74 0.41—1.32 0.306
Alpha-blocker −0.44 0.64 0.20—2.12 0.469
Statin −0.17 0.84 0.47—1.52 0.567
Biguanide 0.28 1.32 0.36—4.88 0.677
Glinide −0.59 0.55 0.02—13.06 0.714
Fibrate −0.22 0.80 0.22—2.95 0.741
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
Table 7 Characteristics of patients with initially diagnosed coronary artery disease according to smoking status.
Persistent
smokers (n = 31)
Quitting
smokers (n = 56)
Former smokers
(n = 113)
Never smokers
(n = 84)
p-Value
Age (years) 60.7± 10.7 57.6± 9.4 65.9± 10.3 67.3± 10.4 <0.0001
Male (%) 87.1 87.5 95.6 60.0 <0.0001
Acute coronary syndrome (%) 67.7 57.1 33.6 46.4 0.001
Multivessel disease (%) 48.4 48.2 51.3 50.0 0.980
LVEF (%) 59.2± 13.5 58.7± 13.0 62.7± 11.8 60.3± 12.4 0.257
Hypertension (%) 71.0 58.9 76.1 70.2 0.150
Dyslipidemia (%) 74.2 89.3 80.5 72.6 0.099
Diabetes (%) 25.8 33.9 31.9 39.3 0.531
Obesity (%) 29.0 42.9 43.4 39.3 0.521
Metabolic syndrome (%) 35.5 44.6 36.3 39.3 0.739
Chronic kidney disease (%) 45.2 39.3 49.6 42.9 0.606
Stroke (%) 3.2 5.4 10.6 13.1 0.313
Peripheral arterial disease (%) 12.9 8.9 11.5 6.0 0.481
Malignancy (%) 3.2 5.4 23.9 10.7 0.001
COPD (%) 6.5 1.8 3.5 2.4 0.636
Dialysis (%) 6.5 8.9 8.0 8.3 1.000
Medical therapy alone (%) 9.7 7.1 15.0 7.1 0.276
Initial successful PCI (%) 87.1 75.0 69.9 85.7 0.033
Initial CABG (%) 3.2 17.9 15.0 7.1 0.072
struc
D
S
A
a
a
c
o
t
A
c
v
a
c
b
[
r
t
A
h
fCABG, coronary artery bypass grafting surgery; COPD, chronic ob
PCI, percutaneous coronary intervention.
iscussion
moking and acute coronary syndrome
CS is a life-threatening disease. If we suffer from
therosclerosis in the coronary artery, it should be avoid-
ble to develop ACS. In the present study, we found that
igarette smoking is an important risk factor for ACS. In
ther words, our results suggest that cigarette smoking is
he ultimate trigger for the onset of ACS rather than SAP.
lso, by quitting smoking after CAD is diagnosed, patients
an avoid subsequent cardiac events relatively early.
In general, to lower the risk of atherosclerosis, all con-
entional risk factors, including hypertension, dyslipidemia,
a
d
c
c
Stive pulmonary disease; LVEF, left ventricular ejection fraction;
nd diabetes, should be treated and smoking should be
eased. Furthermore, metabolic syndrome and CKD have
een identiﬁed as risk factors for cardiovascular disease
13—16]. However, our statistical analysis of all possible
isk factors, including metabolic syndrome and CKD, showed
hat cigarette smoking was the strongest risk factor for
CS.
There are several possible reasons cigarette smoking is so
armful in ACS. Cigarette smoke contains numerous harm-
ul components, including nicotine, carbon monoxide, tar,
nd carbonyl compounds [26]. Interestingly, smoking alone
oes not cause the progression of atherosclerosis [2]. In fact,
igarette smoking acts with other risk factors, such as hyper-
holesterolemia, to accelerate atherosclerosis [2,27,28].
moking may affect the susceptibility of LDL cholesterol in
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rFig. 1 Kaplan—Meier survival curves for free from cardiac eve
a signiﬁcantly lower rate of cardiac event-free survival (74.2%)
plasma to peroxidative modiﬁcation. Modiﬁed LDL choles-
terol is the preferred substrate for macrophages and induces
their subsequent transformation into foam cells [29,30].
Then, why was cigarette smoking identiﬁed as a crucial risk
factor for ACS in this study?
Calcium-channel blockers for the primary
prevention of acute coronary syndrome
In the present study, we also found that CCBs might be
useful for preventing the onset of ACS. Results of previ-
ous studies regarding the use of CCBs for treating ischemic
heart disease in Caucasian patients have been controver-
sial [31,32]. However, these studies suggest that CCBs might
be useful for preventing the onset of ACS, at least in
the present Japanese population. This result regarding pri-
mary prevention was similar to that of a previous study
on secondary prevention in Japan [33]. Importantly, other
agents, including beta-blockers and statins, were not mod-
ulating drugs for ACS in this study, although beta-blockers
and statins are often considered useful for preventing the
progression of coronary atherosclerosis and ischemic heart
diseases.
Acute coronary syndrome and coronary spasm
The two main ﬁndings of the present study — (1) smoking
is a strong risk factor for ACS and (2) CCBs are useful for
preventing the development of ACS — support the notion
that hypercontractility of the coronary arteries or coronary
spasm is strongly associated with the onset of ACS in the
Japanese population. In other words, hypercontractility or
coronary spasm may be a key mechanism of the onset of ACS
in the Japanese population.
Coronary spasm of a major coronary artery is common
in the Japanese population and plays an important role in
the pathogenesis of variant angina as well as in coronary
artery disease in general [34—37]. Endothelial dysfunction
is a key mechanism of coronary spasm; nitric oxide is deﬁ-
cient in the coronary arteries of patients with coronary
spasm [37,38]. Also, as a risk factor for coronary spasm,
s
o
p
s
occording to subsequent smoking status. Persistent smokers had
did quitting smokers (94.6%, log-rank test, p = 0.004).
igarette smoking is more important than other risk factors
35,37,39].
Several possible mechanisms for the contribution of
moking to ACS can be considered. The key mechanism for
he onset of ACS might be endothelial dysfunction induced
y smoking on the basis of coronary atherosclerosis. Nat-
rally, endothelial function is reduced by atherosclerosis
tself. However, in Japanese patients, endothelial func-
ion may be markedly reduced for genetic reasons [40,41].
ndothelial dysfunction induced by cigarette smoking added
o genetic factors induces vascular hypercontractility or
oronary spasm [42]. This combination of smoking and
enetic factors is probably the reason CCBs were extremely
ffective in the present study population. Coronary plaques
ould easily become unstable, and ACS would be likely to
ccur, in a state of vascular hyperconstriction. Cigarette
moke includes various harmful components; however, for
CS the most important are extracts of oxygen-free radicals,
hich inactivate nitric oxide and directly damage endothe-
ial cells [26].
moking cessation for the secondary prevention of
ardiac events
n the present study, we found that cigarette smoking is
n important risk factor for the onset of ACS. Accordingly,
moking cessation has been reported to reduce the risk of
ubsequent cardiac events and mortality in patients with
AD [4—6]. Therefore, patients should be encouraged to
top smoking; however, 42.3% of patients with CAD who
moked in the present study could not quit. In the second
art of this study, we followed up the smoking status of the
atients. Of note, the rate of subsequent cardiac events
ecreased signiﬁcantly in quitting smokers during the short
ollow-up period of 3 years. We speculate that this favorable
esult was due to improved endothelial function through
moking cessation. Thus, because cigarette smoking is the
nly risk factor that patients with CAD can avoid by choice,
atients with CAD should be strongly encouraged to quit
moking as early as possible for the secondary prevention
f cardiac events.
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tudy limitations
ur study has several limitations that should be considered.
irst, because some quitting smokers might have resumed
moking, our study might have underestimated the risk
eduction associated with stopping smoking. Second, we
btained information regarding smoking status from hospi-
al records, a questionnaire, and interviews of patients, but
e did not assess smoking behavior with biochemical tests.
ven if a randomized, controlled trial, which would investi-
ate the long-term effects of smoking cessation in patients
ith newly diagnosed CAD, is ethically problematic, a large-
cale prospective study in Japan may be required. Finally,
n the present study, subjects were patients in whom CAD
eveloped due to a clustering of various risk factors and
ho received their initial diagnosis of CAD at our hospital.
he present study compared characteristics of risk factors
etween patients with ACS and patients with SAP. Smoking is
bviously a risk factor for CAD in general, although Japan’s
inistry of Health, Labour and Welfare reported in 2008 that
he smoking rate in Japan is 21.8%.
onclusions
he risk factors were signiﬁcantly different between ACS and
AP. In conclusion, our comparison of risk factors between
CS and SAP has shown that cigarette smoking is the most
mportant risk factor for ACS among the traditional risk fac-
ors, metabolic syndrome, and CKD. Furthermore, among
he therapeutic agents used for the primary prevention of
AD, CCBs were underprescribed for many patients with
CS. Treatment with CCBs would probably be effective for
reventing ACS in Japanese patients, because CCBs sup-
ress the hypercontractility of the coronary arteries. In
he follow-up portion of our study, we found that smoking
essation helped prevent subsequent cardiac events; thus,
atients with initially diagnosed CAD should be encouraged
o quit smoking as early as possible and should be treated
ith CCBs.
eferences
[1] Friedman GD, Petitti DB, Bawol RD, Siegelaub AB. Mortality in
cigarette smokers and quitters. Effect of base-line differences.
N Engl J Med 1981;304:1407—10.
[2] Willett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA,
Rosner B, Monson RR, Stason W, Hennekens CH. Relative and
absolute excess risks of coronary heart disease among women
who smoke cigarettes. N Engl J Med 1987;317:1303—9.
[3] Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt
D, Diaz R, Rashed W, Freeman R, Jiang L, Zhang X, Yusuf
S, INTERHEART Study Investigators. Tobacco use and risk of
myocardial infarction in 52 countries in the INTERHEART study:
a case—control study. Lancet 2006;368:647—58.
[4] Rosenberg L, Kaufman DW, Helmrich SP, Shapiro S. The risk of
myocardial infarction after quitting smoking in men under 55
years of age. N Engl J Med 1985;313:1511—4.[5] Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of
myocardial infarction among women who stop smoking. N Engl
J Med 1990;322:213—7.
[6] Rea TD, Heckbert SR, Kaplan RC, Smith NL, Lemaitre RN,
Psaty BM. Smoking status and risk for recurrent coronaryH. Yagi et al.
events after myocardial infarction. Ann Intern Med 2002;137:
494—500.
[7] Critchley JA, Capewell S. Mortality risk reduction associated
with smoking cessation in patients with coronary heart disease:
a systematic review. JAMA 2003;290:86—97.
[8] Keys A, editor. Coronary heart disease in seven countries. Cir-
culation 1970; 41:I1—I211.
[9] Fuster V, Badimon L, Badimon JJ, Chesebro JH. The patho-
genesis of coronary artery disease and the acute coronary
syndromes (1). N Engl J Med 1992;326:242—50.
10] Fuster V, Badimon L, Badimon JJ, Chesebro JH. The patho-
genesis of coronary artery disease and the acute coronary
syndromes (2). N Engl J Med 1992;326:310—8.
11] Stary HC. Evolution and progression of atherosclerotic lesions
in coronary arteries of children and young adults. Arterioscle-
rosis 1989;9:I19—32.
12] Ross R. Atherosclerosis—–an inﬂammatory disease. N Engl J Med
1999;340:115—26.
13] Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo
E, Tuomilehto J, Salonen JT. The metabolic syndrome and
total and cardiovascular disease mortality in middle-aged men.
JAMA 2002;288:2709—16.
14] Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK,
Montori VM. Metabolic syndrome and risk of incident cardiovas-
cular events and death: a systematic review and meta-analysis
of longitudinal studies. J Am Coll Cardiol 2007;49:403—14.
15] Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L,
Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K,
Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation
between renal dysfunction and cardiovascular outcomes after
myocardial infarction. N Engl J Med 2004;351:1285—95.
16] Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kid-
ney disease and the risks of death, cardiovascular events, and
hospitalization. N Engl J Med 2004;351:1296—305.
17] Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarc-
tion redeﬁned—–a consensus document of The Joint European
Society of Cardiology/American College of Cardiology Commit-
tee for the redeﬁnition of myocardial infarction. J Am Coll
Cardiol 2000;36:959—69.
18] Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF
Task Force for the Redeﬁnition of Myocardial Infarction, Jaffe
AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J,
Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P,
et al. Universal deﬁnition of myocardial infarction. Circulation
2007;116:2634—53.
19] Okamura T, Tanaka H, Miyamatsu N, Hayakawa T, Kadowaki
T, Kita Y, Nakamura Y, Okayama A, Ueshima H, NIPPON
DATA80 Research Group. The relationship between serum total
cholesterol and all-cause or cause-speciﬁc mortality in a 17.3-
year study of a Japanese cohort. Atherosclerosis 2007;190:
216—23.
20] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the con-
centration of low-density lipoprotein cholesterol in plasma,
without use of the preparative ultracentrifuge. Clin Chem
1972;18:499—502.
21] Examination Committee of Criteria for ‘Obesity Disease’ in
Japan, Japan Society for the Study of Obesity. New criteria
for ‘obesity disease’ in Japan. Circ J 2002;66:987—92.
22] Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA,
Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB,
Rosenﬁeld KA, Sacks D, Stanley JC, Taylor Jr LM, White
CJ, et al. ACC/AHA 2005 Practice Guidelines for the man-
agement of patients with peripheral arterial disease (lower
extremity, renal, mesenteric, and abdominal aortic): a col-
laborative report from the American Association for Vascular
Surgery/Society for Vascular Surgery, Society for Cardiovas-
cular Angiography and Interventions, Society for Vascular
Medicine and Biology, Society of Interventional Radiology,
[[
[
[
[
[
[
[
[
[Difference in risk factors between ACS and stable AP
and the ACC/AHA Task Force on Practice Guidelines (Writ-
ing Committee to Develop Guidelines for the Management
of Patients With Peripheral Arterial Disease): endorsed by
the American Association of Cardiovascular and Pulmonary
Rehabilitation; National Heart, Lung, and Blood Institute;
Society for Vascular Nursing; TransAtlantic Inter-Society Con-
sensus; and Vascular Disease Foundation. Circulation 2006;113:
e463—654.
[23] The International Diabetes Federation. IDF Worldwide Deﬁni-
tion of the Metabolic Syndrome. http://www.idf.org/home/
index.cfm?unode=1120071E-AACE-41D2-9FA0-BAB6E25BA072.
[24] Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata
K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing
the Japanese equation for estimated GFR. Revised equations
for estimated GFR from serum creatinine in Japan. Am J Kidney
Dis 2009;53:982—92.
[25] McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural
history of congestive heart failure: the Framingham study. N
Engl J Med 1971;285:1441—6.
[26] Ambrose JA, Barua RS. The pathophysiology of cigarette smok-
ing and cardiovascular disease: an update. J Am Coll Cardiol
2004;43:1731—7.
[27] Holbrook JH, Grundy SM, Hennekens CH, Kannel WB, Strong
JP. Cigarette smoking and cardiovascular diseases. A statement
for health professionals by a task force appointed by the steer-
ing committee of the American Heart Association. Circulation
1984;70, 1114A—A1117.
[28] Gotto Jr AM. Interactions of the major risk factors for coronary
heart disease. Am J Med 1986;80:48—55.
[29] Yokode M, Kita T, Arai H, Kawai C, Narumiya S, Fujiwara
M. Cholesteryl ester accumulation in macrophages incubated
with low density lipoprotein pretreated with cigarette smoke
extract. Proc Natl Acad Sci USA 1988;85:2344—8.
[30] Harats D, Ben-Naim M, Dabach Y, Hollander G, Stein O, Stein
Y. Cigarette smoking renders LDL susceptible to peroxida-
tive modiﬁcation and enhanced metabolism by macrophages.
Atherosclerosis 1989;79:245—52.
[31] Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related
increase in mortality in patients with coronary heart disease.
Circulation 1995;92:1326—31.
[32] Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan
TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl
PW, Wagner EH, Furberg CD. The risk of myocardial infarc-353
tion associated with antihypertensive drug therapies. JAMA
1995;274:620—5.
33] Japanese beta-blockers and calcium antagonists myocardial
infarction (JBCMI) investigators. Comparison of the effects of
beta blockers and calcium antagonists on cardiovascular events
after acute myocardial infarction in Japanese subjects. Am J
Cardiol 2004;93:969—73.
34] Yasue H, Omote S, Takizawa A, Nagao M. Coronary arterial
spasm in ischemic heart disease and its pathogenesis. A review.
Circ Res 1983;52:I147—52.
35] Maseri A, Davies G, Hackett D, Kaski JC. Coronary artery spasm
and vasoconstriction. The case for a distinction. Circulation
1990;81:1983—91.
36] Yasue H, Kugiyama K. Coronary artery spasm: Japanese view.
Coronary artery disease 1990;1:668—73.
37] Yasue H, Nakagawa H, Itoh T, Harada E, Mizuno Y. Coronary
artery spasm—–clinical features, diagnosis, pathogenesis, and
treatment. J Cardiol 2008;51:2—17.
38] Kugiyama K, Yasue H, Okumura K, Ogawa H, Fujimoto K, Nakao
K, Yoshimura M, Motoyama T, Inobe Y, Kawano H. Nitric oxide
activity is deﬁcient in spasm arteries of patients with coronary
spastic angina. Circulation 1996:266—72.
39] Takaoka K, Yoshimura M, Ogawa H, Kugiyama K, Nakayama M,
Shimasaki Y, Mizuno Y, Sakamoto T, Yasue H. Comparison of the
risk factors for coronary artery spasm with those for organic
stenosis in a Japanese population: role of cigarette smoking.
Int J Cardiol 2000;72:121—6.
40] Yoshimura M, Yasue H, Nakayama M, Shimasaki Y, Sumida H,
Sugiyama S, Kugiyama K, Ogawa H, Ogawa Y, Saito Y, Miyamoto
Y, Nakao K. A missense Glu298Asp variant in the endothelial
nitric oxide synthase gene is associated with coronary spasm in
the Japanese. Hum Genet 1998;103:65—9.
41] Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K,
Ogawa H, Motoyama T, Saito Y, Ogawa Y, Miyamoto Y, Nakao K.
T-786–>C mutation in the 5′-ﬂanking region of the endothelial
nitric oxide synthase gene is associated with coronary spasm.
Circulation 1999;99:2864—70.
42] Nakayama M, Yoshimura M, Sakamoto T, Shimasaki Y, Nakamura
S, Ito T, Abe K, Yamamuro M, Miyamoto Y, Saito Y, Nakao K,
Yasue H, Ogawa H. Synergistic interaction of T-786–>C polymor-
phism in the endothelial nitric oxide synthase gene and smoking
for an enhanced risk for coronary spasm. Pharmacogenetics
2003;13:683—8.
